Targeting IL-22 is particularly promising as an alternative strategy to directly break the cycle of inflammatory cytokine and chemokine signaling, and the fusion protein using the IL-22 gene and nanocomplex is considered a new strategy to improve liver disease (Chen et al., 2017; Chen et al., 2018; Chen et al., 2020). The gene discussed is IL22; the disease is liver disorder.